PCSK9 and familial hypercholesterolemia: Taken together, the published evidence from the phase 2 trials suggests that PCSK9 inhibition with monoclonal antibodies is an effective and well tolerated treatment option for a diverse patient populationswith hypercholesterolemia over a 12-week treatment period.